Related Experiment Video
Updated: May 12, 2026
Development of Compendium for Esophageal Squamous Cell Carcinoma
Published on: April 12, 2024
Immunohistochemical analysis on potential new molecular targets for esophageal cancer
1Department of General and Visceral Surgery, University of Muenster, Muenster, Germany.
Abstract:
Despite multimodal therapeutic options, esophageal cancer is still among the most deadly malignancies. In the past decade, targeted therapy has shown great potential in other cancers, but data on esophageal carcinoma are still rare. Five potential new molecular targets in esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC) were investigated for their expression characteristics: vascular endothelial growth factor receptor (VEGFR)-3, human epidermal growth factor receptor-2, stem cell growth factor receptor, tissue inhibitors of metalloproteinase (TIMP)-4 and TIMP-3. One hundred seventy-one EAC and ESCC tissue samples obtained from patients undergoing esophagectomy from 2000 to 2008 were included. Clinical data were evaluated retrospectively. Immunohistochemical staining was performed using tumor tissue with and without neoadjuvant treatment and healthy tissue. For samples without neoadjuvant treatment, expression of all targets was higher in tumor tissue than in healthy tissue except for VEGFR-3 (>98% expression in both tissues). For TIMP-4, TIMP-3 and stem cell growth factor receptor, trends to higher expression in tumor tissue were also found in EAC and ESCC that had received neoadjuvant treatment. Using Matched-pair analysis, we compared target expression in tumor tissue with and without neoadjuvant treatment. Only TIMP-3 had significantly lower expression in neoadjuvant treated tumor tissue (EAC: P = 0.059, ESCC: P = 0.006). TIMP-4, TIMP-3 and VEGFR-3 appear to qualify for targeted therapy in esophageal cancer because of their high expression in neoplastic tissue. TIMP-3 appears to be downregulated in neoadjuvantly treated esophageal cancer, and VEGFR-3 shows high expression in healthy mucosa leading to severe side effects by molecular targeting. Thus, TIMP-4 seems the most promising target.
Insights
Targeted therapy shows promise for esophageal cancer. Researchers found Tissue Inhibitor of Metalloproteinase (TIMP)-4 highly expressed in tumors, making it a potential target for esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC).
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Esophageal cancer remains a deadly malignancy despite various treatments.
- Targeted therapy has advanced other cancers, but its role in esophageal carcinoma is less understood.
- Identifying novel molecular targets is crucial for improving treatment efficacy.
Purpose of the Study:
- To investigate the expression of five potential molecular targets in esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (ESCC).
- To evaluate the suitability of these targets, including vascular endothelial growth factor receptor (VEGFR)-3, human epidermal growth factor receptor-2, stem cell growth factor receptor, tissue inhibitors of metalloproteinase (TIMP)-4, and TIMP-3, for targeted therapy.
- To assess the impact of neoadjuvant treatment on target expression.
Main Methods:
- Retrospective analysis of 171 EAC and ESCC tissue samples from patients who underwent esophagectomy (2000-2008).
- Immunohistochemical staining to evaluate target expression in tumor tissue (with and without neoadjuvant treatment) and healthy tissue.
- Matched-pair analysis to compare target expression before and after neoadjuvant treatment.
Main Results:
- Most targets, except VEGFR-3, showed higher expression in tumor tissue compared to healthy tissue before neoadjuvant treatment.
- TIMP-4, TIMP-3, and stem cell growth factor receptor showed trends of higher expression in neoadjuvantly treated EAC and ESCC.
- TIMP-3 expression was significantly lower in neoadjuvantly treated tumor tissue (EAC: P = 0.059, ESCC: P = 0.006).
- VEGFR-3 exhibited high expression in healthy mucosa, potentially causing side effects with molecular targeting.
Conclusions:
- TIMP-4, TIMP-3, and VEGFR-3 are potential candidates for targeted therapy in esophageal cancer due to their expression in neoplastic tissue.
- TIMP-3 downregulation after neoadjuvant treatment and VEGFR-3's expression in healthy tissue suggest limitations.
- TIMP-4 emerges as the most promising molecular target for esophageal cancer therapy.
